Pillar 2 Cannabis Pilot Program to Launch in Germany

Germany is advancing its cannabis policy by launching “Pillar 2,” a five-year pilot project to explore the effects of legalizing cannabis for adults. In doing so, Germany aims to create a sustainable regulatory model based on successful examples from Swiss research which can serve as a blueprint for other countries looking at implementing similar drug policy reforms.

For more news like this, along with all the latest in legalization, research, and lifestyle, download our free cannabis news app.

Background to Germany’s Pillar 2 Program

Over the last few decades, we have witnessed a global shift in drug policy, where cannabis is gradually ceasing to be treated as a threat on par with the most severe drugs and is beginning to be viewed through the lens of its potential benefits, both medical and economic. This reevaluation process began in the United States and Canada but quickly spread to many European countries, including Switzerland, which has become a pioneer in studying the impact of cannabis regulation on society.

Observing the experiences of its European neighbors, Germany has also decided to change its approach to cannabis. The introduction of “Pillar 1,” which decriminalized possession, consumption, home cultivation, and the creation of cannabis associations, was the first step toward regulating this market. “Pillar 2,” modeled on Swiss research, takes this initiative even further.

Understanding “Pillar 2”

“Pillar 2” involves launching five-year pilot projects in various German states to investigate the effects of legalizing cannabis for adult users. These initiatives aim not only to gather scientific data on the impact of such changes on crime, public health, and the economy but also to test different market regulation models. This approach allows for flexible adjustment of regulations to local conditions, which is crucial in Germany’s federal system.

These initiatives differ from “Pillar 1,” which focused more on reducing social harms resulting from the criminalization of cannabis. “Pillar 2” focuses on creating a sustainable model that could serve as a template for future regulations on a larger scale.

Reasons for Accelerating Work

The decision to accelerate the implementation of “Pillar 2” was driven by several factors. Firstly, Germany could take advantage of existing legal infrastructure thanks to the CanG Act, which allows for the use of cannabis for scientific purposes unrelated to medicine. This bypassed the lengthy legislative process, which is crucial in a rapidly changing political and social environment.

Secondly, by leveraging Swiss experiences, Germany was able to adopt proven solutions and avoid potential pitfalls. Switzerland, which has already approved seven pilot trials, provided valuable knowledge on organizing, monitoring, and evaluating projects, significantly speeding up the possibility of implementing similar solutions in Germany.

As a result, “Pillar 2” has the potential not only to change the German approach to cannabis but also to serve as a model for other countries considering similar reforms. Germany, with its central location in Europe and strong economic position, can play a crucial role in shaping the future of drug policy on the continent.

Key Figures and Their Role

Finn Age Hänsel: Catalyst for Change in German Cannabis Policy

Finn Age Hänsel, serving as the managing director at Sanity Group, plays a key role in the implementation of “Pillar 2” in Germany. Hänsel, who has extensive experience in both the German and Swiss cannabis markets, applies his knowledge to promote effective and pragmatic approaches to market regulation. Through his work at Sanity Group, the company has become one of the main players in the European cannabis industry, and Hänsel has gained a reputation as an innovator and strategist.

Hänsel often emphasizes the importance of a solid scientific and regulatory foundation for the future development of the cannabis market. His involvement in pilot projects in Switzerland, and now in Germany, shows his commitment to creating models that can serve as examples of good practice internationally.

Luc Richner: Technological Architect of the Cannabis Market

Luc Richner, co-founder and CEO of Cannavigia, provides technologies that are crucial for effective control and management of cannabis sales. Cannavigia, with its flagship product—a system for managing cannabis dispensaries, enables tracking and monitoring the entire supply chain from cultivation to final sale. Richner, using his technical and entrepreneurial skills, supports German companies and local governments in preparing for upcoming regulations.

Cannavigia systems, already used in Swiss pilot projects, offer unprecedented transparency and compliance with regulations, which is essential in the context of tightening European cannabis regulations. Richner, like Hänsel, is convinced that technology plays a key role in modernizing and improving cannabis markets.

Future Actions and Expectations

In the context of upcoming actions, the German government focuses on public consultations and collecting feedback before finalizing the regulations concerning “Pillar 2.” This consultation period, which is to end in May, is crucial for understanding and addressing societal, business, and scientific concerns.

The rapid implementation of “Pillar 2,” anticipated later this year, is expected to bring many benefits. For entrepreneurs, it opens the door to a new market and product innovations. For scientists, it provides an opportunity to conduct research under real conditions. For society, it means access to more reliable information and potentially reduced crime associated with the black market.

The implementation of “Pillar 2” is not only a step towards a more liberal and informed drug policy in Germany but also potentially a model for other countries considering similar reforms. As imminent changes approach, Germany can not only revolutionize its own approach to cannabis but also become a leader in the European debate on regulating this substance.

—

(Featured image by Maheshkumar Painam via Unsplash)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Fakty Konopne, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.